Zoetis (ZTS) Competitors

Zoetis (NYSE:ZTS) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.

Does the MarketBeat Community favor ZTS or ABBV?

AbbVie received 427 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.97% of users gave Zoetis an outperform vote while only 73.40% of users gave AbbVie an outperform vote.

Company	Underperform	Outperform
Zoetis	Outperform Votes 906 77.97%	Underperform Votes 256 22.03%
AbbVie	Outperform Votes 1333 73.40%	Underperform Votes 483 26.60%

Do institutionals & insiders believe in ZTS or ABBV?

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.3% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is ZTS or ABBV more profitable?

Zoetis has a net margin of 26.55% compared to AbbVie's net margin of 9.22%. AbbVie's return on equity of 244.01% beat Zoetis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	26.55%	51.98%	18.41%
AbbVie	9.22%	244.01%	13.44%

Which has more volatility and risk, ZTS or ABBV?

Zoetis has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Do analysts prefer ZTS or ABBV?

Zoetis presently has a consensus target price of $221.44, indicating a potential upside of 26.06%. AbbVie has a consensus target price of $203.37, indicating a potential upside of 21.24%. Given Zoetis' stronger consensus rating and higher possible upside, research analysts plainly believe Zoetis is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
AbbVie	0 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.90

Does the media prefer ZTS or ABBV?

In the previous week, AbbVie had 56 more articles in the media than Zoetis. MarketBeat recorded 81 mentions for AbbVie and 25 mentions for Zoetis. Zoetis' average media sentiment score of 1.29 beat AbbVie's score of 1.16 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	22 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	56 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Is ZTS or ABBV a better dividend stock?

Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.0%. AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.7%. Zoetis pays out 32.5% of its earnings in the form of a dividend. AbbVie pays out 215.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis has increased its dividend for 13 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has higher earnings & valuation, ZTS or ABBV?

AbbVie has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$8.54B	9.28	$2.34B	$5.32	33.02
AbbVie	$54.32B	5.46	$4.86B	$2.88	58.24

Summary

Zoetis beats AbbVie on 11 of the 21 factors compared between the two stocks.